Staar Surgical Co

STAA is trading with an RSI of 68.0—approaching overbought territory—yet maintains a modest $1.3B market cap and trades below its 52-week high, suggesting limited euphoria despite recent momentum. The absence of a P/E ratio indicates either recent unprofitability or unusual capital structure, which raises questions about earnings quality. For a specialized ophthalmic device maker, this combination of technical heat without euphoric valuations could signal either a genuine rerating of a turnaround story or a squeeze setup in a thinly-traded name. The missing short float data obscures visibility into potential squeeze dynamics, making the elevated RSI particularly ambiguous—it could reflect genuine strength in a recovering business or temporary momentum in a micro-cap prone to outsized moves.